Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety

Bahouth, Fadel; Chutko, Boris; Sholy, Haitham; Hassanain, Sabreen; Zaid, Gassan; Radzishevsky, Evgeny; Fahmwai, Ibrahem; Hamoud, Mahmod; Samnia, Nemer; Khoury, Johad; Dobrecky-Mery, Idit

doi:10.3390/medicines12020013

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.

Open AccessArticle

Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety

by

Fadel Bahouth

^1,*

,

Boris Chutko

¹,

Haitham Sholy

¹

,

Sabreen Hassanain

¹,

Gassan Zaid

¹,

Evgeny Radzishevsky

¹,

Ibrahem Fahmwai

¹,

Mahmod Hamoud

¹,

Nemer Samnia

¹,

Johad Khoury

^2,*,†

and

Idit Dobrecky-Mery

^1,†

¹

Department of Cardiology, Bnai-Zion Medical Center, Haifa 31096, Israel

²

Pulmonology Division, Carmel Medical Center, Haifa 3436212, Israel

^*

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Medicines 2025, 12(2), 13; https://doi.org/10.3390/medicines12020013

Submission received: 28 December 2024 / Revised: 22 April 2025 / Accepted: 6 May 2025 / Published: 14 May 2025

Download Versions Notes

Abstract

Introduction: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. Purpose: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatelet drugs, after about a decade of practical use. Methods: A retrospective observational study included all patients who were admitted with acute coronary syndrome between January 2010 and December 2019 and were discharged with aspirin and either prasugrel or ticagrelor after percutaneous coronary intervention. Patients were divided into two groups based on the dual antiplatelet drugs prescribed. Primary endpoint: A composite endpoint of cardiovascular death, recurrent coronary syndrome, or ischemic stroke at one year. Secondary endpoint: Significant bleeding according to the BARC classification (types 3, 4, or 5). Results: During this period, 746 patients met the inclusion criteria. The primary endpoint was reached in 70 patients (9.4%): 24 patients (8.0%) in the group treated with ticagrelor and 46 patients (10.3%) in the group treated with prasugrel (p-value = 0.303). In terms of safety events, significant bleeding was not statistically different between the ticagrelor and prasugrel groups: 13 (2.9%) vs. 9 (3%), respectively (p-value = 0.9). More patients discontinued their treatment before the end of the year among those treated with ticagrelor compared to those treated with prasugrel. [16.7% vs. 9.6%, p-value = 0.003). Conclusions: There was no significant difference in the occurrence of recurrent cardiac events, stroke, or cardiovascular death, nor significant bleeding among ACS patients treated either with prasugrel or ticagrelor.

Keywords: acute coronary syndrome; ticagrelor; prasugrel; dual anti platelet drugs

Share and Cite

MDPI and ACS Style

Bahouth, F.; Chutko, B.; Sholy, H.; Hassanain, S.; Zaid, G.; Radzishevsky, E.; Fahmwai, I.; Hamoud, M.; Samnia, N.; Khoury, J.; et al. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines 2025, 12, 13. https://doi.org/10.3390/medicines12020013

AMA Style

Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, et al. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines. 2025; 12(2):13. https://doi.org/10.3390/medicines12020013

Chicago/Turabian Style

Bahouth, Fadel, Boris Chutko, Haitham Sholy, Sabreen Hassanain, Gassan Zaid, Evgeny Radzishevsky, Ibrahem Fahmwai, Mahmod Hamoud, Nemer Samnia, Johad Khoury, and et al. 2025. "Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety" Medicines 12, no. 2: 13. https://doi.org/10.3390/medicines12020013

APA Style

Bahouth, F., Chutko, B., Sholy, H., Hassanain, S., Zaid, G., Radzishevsky, E., Fahmwai, I., Hamoud, M., Samnia, N., Khoury, J., & Dobrecky-Mery, I. (2025). Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines, 12(2), 13. https://doi.org/10.3390/medicines12020013

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI